Maryland Cigarette Restitution Fund Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2020
NCT04331717
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Maryland Cigarette Restitution Fund

Active Ingredients

Drugs in Phase 2 Trials (1)

leuprolide (lupron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Obesity, Morbid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1